ser-155
ser-155: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Seres Therapeutics, Inc. (MCRB) | Phase 2 |
FDA Decisions
FDA_MeetingFDA granted Breakthrough Therapy designation to SER-155 in December 2024 for reduction of bloodstream infections in adults undergoing allo-HSCT.(MCRB)
Frequently asked questions
Who is developing ser-155?
ser-155 is being developed by Seres Therapeutics, Inc..
What is ser-155's latest FDA decision?
The most recent tracked FDA decision for ser-155 is FDA_Meeting for FDA granted Breakthrough Therapy designation to SER-155 in December 2024 for reduction of bloodstream infections in adults undergoing allo-HSCT..
Get deeper analysis on ser-155
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis